What's Hot
View all perspectives
David Liew drdavidliew
1 year ago
International collaborative has discussed early referrals for PMR - this is what they’re recommending
Better plans to get the right patients into rheumatologists is a big part of helping #MakeRheumForPMR
ABST2395 #ACR23 @RheumNow https://t.co/Kea07IGxhG
Richard Conway
1 year ago
Antifibrotics in RA-ILD @Juge_P_A Discontinuation in 46% (Mainly GI). Improved FVC trajectory - almost stops decline. Abstr#2479 #ACR23 #ACRbest @RheumNow https://t.co/nZW6TVKefL https://t.co/5BX3PhFhOK
Meral K. El Ramahi, MD MeralElRamahiMD
1 year ago
Rashes in Rheumatology at #ACR23
Name the rash? @Rheumnow https://t.co/7CNqOESctW
Md Yuzaiful Md Yusof
1 year ago
#ACR23 Abstr#2334 Can we achieve #SLE DORIS remission with current therapy? Post-hoc analyses of 3 x RCTs + LTE over 4 years showed anifrolumab therapy was associated with more frequent and sustained remission vs PBO during the 4-year period. Good for long-term outcomes @RheumNow https://t.co/eq02yChTZr
Meral K. El Ramahi, MD MeralElRamahiMD
1 year ago
Rashes in Rheumatology at #ACR23
Name the rash? @Rheumnow https://t.co/uFjXEOHczZ
David Liew drdavidliew
1 year ago
Dysautonomia & joint hypermobility/hEDS - we all know that patients often have both, but what groups of symptoms cluster for patients?
This French study showed three main groups - need to look at treatment strategies for each group individually
#ACR23 ABST1838 @RheumNow https://t.co/UDepsudpXx
Eric Dein
1 year ago
TM83 #ACR23 @RheumNow
45yo M b/l sacroiliitis, Rx MTX -> ADA -> MTX + Tofa. No improv
Low Ca, & Phos, ALP 239. Nml Vit D, High PTH.
DEXA: Osteoporosis
FGF23 high
PET/CT showed soft tissue density in nasal septum, few cortical breaks
Dx: oncogenic osteomalacia 2/2 malignancy https://t.co/EOcYNtovBy
Meral K. El Ramahi, MD MeralElRamahiMD
1 year ago
Review of rashes in SLE at #ACR23 by Dr. Katherine Shaw, MD
⭐️Important to recognize rashes of lupus b/c heterogeneity of cutaneous lupus erythematosus subtypes influences response to treatment.
@RheumNow https://t.co/u7dwDe9kbt
David Liew drdavidliew
1 year ago
Real-world tolerability of anti-fibrotics (nintedanib, pirfenidone) in RA-ILD @BrighamWomens:
patients do drop out because of AEs, but a decent chunk are okay and do get modest benefit
@Juge_P_A @jeffsparks #ACR23 ABST2479 @RheumNow https://t.co/BpM14eizmF
Meral K. El Ramahi, MD MeralElRamahiMD
1 year ago
⭐️Important to recognize rashes of lupus b/c heterogeneity of cutaneous lupus erythematosus subtypes influences response to treatment.
🚩Phase II trial of Iberdomide in SLE:
➡️ not associated w/ statistically significant improvement in CLASI-A when including ALL CLE subtypes… https://t.co/LHNqKMALzU https://t.co/K73sXjFTHM
Eric Dein
1 year ago
TM84 #ACR23 @RheumNow
49F MS on RTX, severe arthralgias/wt loss, BMI 18. Spontaneous peritonitis, aseptic discitis/osteo, distal radius lucency, hyperammonemia, hypogammaglobulinemia w 1 yr arthritis
Dx: Mycoplasma: ureaplasma urealyticam on culture, PCR improved https://t.co/jM0sARLZS7
Dr. John Cush RheumNow
1 year ago
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow
1 year ago
Watch: Correlation Between Patient and Physicians Assessments in PsA Save
Dr. Antoni Chan interviews Dr. Avin Maroof at the 2023 ACR Convergence meeting in San Diego, CA. #ACR23
https://t.co/syG4Ry08vF https://t.co/6g9SpISSIt
Bella Mehta bella_mehta
1 year ago
Merging field moving forward - cardio-rheumatology collaboration imp!
Calcium scores in older patients with #RA may be the one take away! Very important to risk predict and mitigate CV events .
Ofcourse history taking still remains key! session 14T118 #ACR23 @RheumNow https://t.co/xoldFlA8EW
Md Yuzaiful Md Yusof
1 year ago
#ACR23 Late-Breaking Abstr#L13 CAR-T is in CT but not RCT yet. Preliminary results from open label (N=3 #SLE of YTB323 (rapcabtagene autocel CD19 directed with preserved T cell stemness) showed favourable CAR T expansion, B cell depletion, early efficacy & safety @RheumNow https://t.co/UQUOfDbFJe
Poster Hall